Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

PLx Pharma Inc. (PLXP)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.3600+0.0500 (+2.16%)
At close: 04:00PM EDT
Advertisement
Sign in to post a message.
  • J
    Jerome
    Anyone heard the JMP conference talk? Clearly they are still looking for a long-term financing situation...
  • r
    robert
    So what about this idea? They claim this so called “BK” so Beyer can swoop in to buy them out for Pennie’s on the dollar?
    If it were me…I’d sell Beyer rights to Vazalore but maintain the rights to their patented delivery system to use in other medication going forward.
    Gary Balkema who’s is director on PLXP’s BoD has ties to Beyer.
    Just throwing it out there.
  • g
    gavin
    I’m still bullish. Been wiping my tears the past ~6 months. I’ve been buying the rumor for years but I should have sold the news back at $20/per. I’ll still take another 10x from these prices. Good value right now
    Bullish
  • J
    Jerome
    This drop is ominous the day before earnings call. At this valuation, it looks like BK is possible. Why didn't they raise funds sooner if they needed more time to ramp up sales? Total mismanagement in terms of communication, etc. In the last CC, they mentioned they were seeing "velocity' in the last few weeks...so which is it? Is it taking off or not? It seems that people have ways to check channels so I am assuming it is bad...
  • J
    Jerome
    Profit taking? Strange drop today...
  • J
    Jerome
    Incredibly cheap if top management can find a non dilutive way to bridge financing to success. That's what they claimed to be able to achieve during CC. Stock jumped to $3 in short order, now back down to close to pre CC/earnings release levels. So the market has just given up on them?
  • s
    scott
    This thing is flirting with a two handle! I can't decide if the current price is a gift or if its going under. I am betting on the former. Two weeks until we hear something from the company. Its got sophisticated backers and experienced management.

    I hope we hear something encouraging.
  • J
    Jerome
    I guess we will get answers tomorrow. Retail investors are always the last ones to learn about these things...
  • J
    Jerome
    Are we going to do a secondary or can we start issuing debt now that we have a commercial product? It would be nice to avoid dilution at these rock bottom prices.
  • J
    Jerome
    It is absurd. We are back at a valuation where CFO and CEO bought recently.
  • J
    Jerome
    The meltdown continues. Usually, this movie does not end well...not sure the product is selling. Certainly priced for a dud on the product market...so promising...yet...

    The firm at this point needs to come out and reassure the market or say something. It is almost priced for bankruptcy...
  • r
    richard
    I READ.....Michael Valentino BIO.....VERY IMPRESSIVE ...
    Executive Chairman of the Board

    Mr. Valentino has served as Executive Chairman of the Board since July 2011 and brings over 40 years of experience in the healthcare industry, including a broad range of critical leadership positions at both major pharmaceutical companies and venture-backed start-ups. In June 2003, Mr. Valentino successfully built start-up Adams Respiratory Therapeutics into a fully integrated specialty pharmaceutical company with more than $490 million in annual revenue and leading OTC brands such as Mucinex® and Delsym®. Under his leadership, Adams completed its initial public offering in July 2005, which was ranked by The Wall Street Journal as the No. 1 Health Care IPO in 2005, and in December 2007, the Company entered into a definitive agreement under which it would be acquired by Reckitt Benckiser, a world leader in household cleaning, health, and personal care, for approximately $2.3 billion. Previously, Mr. Valentino was President and Chief Operating Officer at Alpharma, a leading global generic pharmaceutical company. Prior to joining Alpharma, he served as Executive Vice President, Global Head Consumer Pharmaceuticals for Novartis AG. He earlier served as President and Chief Operating Officer of Novartis Consumer Healthcare, North America. Mr. Valentino was also President of Pharmacia & Upjohn’s Consumer Products Division. Throughout his career, Mr. Valentino has been at the forefront of 7 major prescription-to-OTC switches, including such well-known consumer brands as Benadryl®, Rogaine Extra Strength®, Motrin Jr.®, Nasalcrom®, Lamisil®, Voltaren (EU), and Mucinex®. He currently serves as a Board Member of Assisted4Living Inc. (ASSF: OTC), a post-acute provider of healthcare from birth through end of life. Mr. Valentino has also served as Chairman of the Consumer Healthcare Products Association.
  • J
    Jerome
    What happens to this company when they show the huge demand for aspirin delivered through their unique FDA approved method. A big pharma will come and scoop them up...but the price tag won't be $500M (current market cap)....think $1-$2Bn...so it is an easy double from here. Just buy now and wait 1-2 years for the firm to do its magic on the marketing/distribution front.
  • s
    scott
    First quarter earnings release to be on Friday the thirteenth.
  • T
    Thomas
    It certainly looks like PLXP is being set up for a traditional short squeeze. On January 8, short interest has grown to 9.8 days of average trading volume. My read is that the national advertising campaign will drive top line revenues significantly. However, IMHO profitability will take longer to materialize. Please remember that this company’s technology can be applied to any number of other meds that have stomach disruption issues. Many meds need to be subcutaneously injected or infused into a vein at greater expense because they are too disruptive to be taken orally. Once PLx Pharma proves the effectiveness of its technology, many other therapeutics will be in the pipeline. This will not be a short-term victory, but there is sophisticated money backing this company. Such sponsors have long-term expectation. We investors should have patience, too.
    Bullish
  • r
    rob
    Seen Vazalore online for sale today. That should be good news right?
  • s
    scott
    What is happening to this stock? What am I missing? They have a real product with what appears to be a decent future.
  • E
    Erik
    They now have the funding to do a national launch of their lead product. They paid off the remaining debt in FEB and raised 74 million in a small offering of about 9mil shares @ $8.00 a share. Quarter 3 is the expected rollout for the new FDA approved drug Vazalore in 325mg and 81mg capsules. Vazalore is a liquid filled asprin capsule that is intended for people who have stomach issues, like ulcers, who otherwise would have a hard time taking asprin. This new drug will help anyone who would benefit from taking asprin but previously could not considering asprin can be hard on the stomach. Once the rollout of this new drug happens this company's revenue's are going to begin increasing exponentially. With no revenue on the books for 2021 so far and a market cap of 250million this stock truly has the potential to take off. Once the drug starts hitting the shelves I can easiliy see a new market cap of 500mil - 1 billion in no time. If you invest now that is double to quadruple your money by the end of 2021. Start studying the price of this stock it swings up and down very easily. Wait for a small 4 -5 % dip and jump in. After that hold, be patient, and watch the your money grow. Very bullish on this stock for 2021-2022. Come 2023 this could be a well established company with over 1bil market cap. By that time your money will have doubled potentially 10X. Best of luck to everyone!
    Bullish
  • M
    Michael
    I started a position at $12 today and plan to hold 18-24mo. I found PLXP thru Thomas Barton as he thinks it could be a 5x over the long term. Looking forward to launch and if we can get to $25m rev by Q4 2022 then should be $25 PPS...Always a BO possibility but not counting on that for a nice gain...I may to walgreens and buys some myself in September ;)...good luck
  • v
    valuegeek77
    According to latest presentation Vazalore will be ~$25/month ($300 per year). The target patient population is huge ~41 million.

    Think about this..

    On the pessimistic side
    If they convert 2% population from EC to Vazalore ~ 250 million revenue
    If they convert 5% population from EC to Vazalore ~ 600 million revenue
    If they convert 10% population from EC to Vazalore ~ 1.2 billion revenue

    On optimistic side
    If they convert 25% population from EC to Vazalore ~ 3 billion revenue

    If this drug turns out to be highly effective compared to EC and in the long run it becomes standard of care ~ 5-6 billion revenue

    Not pumping, just laying out possibilities.

    Market is highly underestimating the potential.
Advertisement
Advertisement